在初级紫外线黑色素瘤中,局部和全身抗瘤反应不同
Francesca Lucibello1, Ana I Lalanne2,3, Anne-Laure Le Gac1
1Department of Immunity and Cancer, Inserm U932, Paris Sciences et Lettres (PSL) University, Institut Curie, Paris, France.
The Journal of experimental medicine
|April 2, 2024
概括
带有染色体3损失的卵巢黑色素瘤 (UM) 显示T淋巴细胞透率增加,这表明局部抗瘤反应. 研究人员对这些T细胞进行了表征,在局部的UM中发现了特定的抗瘤反应.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 卵巢黑色素瘤 (UM) 是最常见的初级眼睛癌.
- 在UM中失去3号染色体 (M3) 与高转移风险相关.
- 在M3瘤中,T淋巴细胞的透率高于异体-3 (D3) 瘤,但它们的作用尚不清楚.
研究的目的:
- 为了表征透到T细胞的原发性毛细膜黑色素瘤.
- 调查T细胞是否在UM中代表抗瘤反应.
- 探索眼睛内的T细胞原始化机制.
主要方法:
- 流细胞计量量化CD8+和Treg细胞.
- 色剂染色 (HLA-A2:Melan-A) 用于识别瘤抗原特异性T细胞.
- 单细胞RNA测序 (scRNAseq-VDJ) 和TCR测序用于克隆扩张分析.
主要成果:
- 与D3瘤相比,M3瘤显示CD8+和Treg细胞的丰度更高.
- 在M3瘤中的CD39+PD-1+CD8+T细胞的丰富,表明特定的抗瘤反应.
- scRNAseq-VDJ和TCRseq揭示了增殖的CD8+T细胞克隆扩张,证实了局部抗瘤反应.
结论:
- 局部化阴道黑色素瘤表现出瘤抗原特异性T细胞反应.
- 这些反应的存在引发了关于在眼睛中没有已知的淋巴排水的情况下的原始化机制的问题.
更多相关视频
相关概念视频
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K


